Author of

• 35377

  +

  P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology (ID 153)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35383

    +

    P14.03 - Histotype-dependent Associations of LAG-3 Expression with Clinicopathologic Features and Survival in Non-small Cell Lung Cancer (ID 1194)

    00:00 - 00:00  |  Presenting Author(s): Dan Shepherd
    • Abstract
    • Slides

    Introduction
    

    Immune checkpoint blockade targeting the PD-1/PD-L1 axis has become a mainstay of treatment for advanced non-small cell lung cancer. However, only a subset of patients benefits, with long-term efficacy limited by primary and secondary resistance. Resistance to PD-1 axis blockade is attributed in part to the upregulation by T-lymphocytes of regulatory molecules such as lymphocyte activation gene-3 (LAG-3). This study examined the role of LAG-3+ T-lymphocytes in the lung adenocarcinoma microenvironment through correlation with clinicopathologic features and patient outcomes.

    Methods
    

    Immunohistochemistry for LAG-3 and CD8 was performed on 225 lung adenocarcinomas resected in 2010-2012 using tissue microarrays (duplicate of 2-mm core). The number of LAG-3+ lymphocytes was quantified in 3 high-power fields (HPF; each 0.24 mm²) for each of the two duplicate samples, and CD8+ tumor-associated lymphocytes (both stromal and tumor-infiltrating) were also quantified. LAG-3+ lymphocytes, CD8+ T-cells, and the ratio of LAG-3+/CD8+ T-cells were correlated with clinicopathologic features, PD-L1 expression, and patient outcomes.

    Results
    

    In lung adenocarcinomas from 225 patients (141 women, 84 men; age 39-89 [median 69] years; 79% smokers; 88% stages 1-2; 40.4% KRAS-mutant; 21.3% EGFR-mutant), the number of LAG-3+ cellsranged from 0 to 540.1/mm² (median 7.0/mm²), and the number of CD8+ tumor-associated lymphocytes ranged from 34.8 to 5205.3/mm² (median 626.7/mm²). Higher numbers of LAG-3+ cells were associated with smoking history (p<0.001) and features of aggressive tumor behavior, including solid-predominant histologic pattern, presence of lymphovascular invasion, and presence of nodal metastasis (all p<0.01). Larger overall tumor size and invasive tumor size correlated with LAG-3+ cells when normalized to CD8+ cell counts (LAG-3/CD8 ratio; p<0.05). In terms of molecular features, KRAS-mutant tumors were associated with significantly higher numbers of LAG-3+ cells versus EGFR-mutant tumors (p<0.01). LAG-3+ cell count was positively correlated with both PD-L1 H score and CD8+ tumor-associated lymphocytes (all p<0.01). Lastly, patients with tumors harboring an increased LAG-3/CD8 ratio (i.e., above the median) showed significantly worse overall survival, irrespective of PD-L1 expression (p=0.027).

    Conclusion
    

    Increased LAG3+ T-lymphocytes were associated with smoking history, adverse histologic features, worse survival, and increased PD-L1 expression in lung adenocarcinomas. Given the known role of LAG-3 in dampening the immune response, high LAG-3 expression may be associated with decreased efficacy of PD-1 axis blockade. Additional studies to evaluate the predictive value of LAG-3 in patients with lung adenocarcinoma undergoing immune checkpoint blockade are warranted.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.